Join Free For Buyer|Sign In

Professional Online Trade Platform for API, Preparation and Pharmaceutical Machinery and Equipment_EN-CPhI.cn

You are here:  Home >>  News >>  Research & Development >>  Shionogi Concludes Licensing Agreements with Eddingpharm for Lusutrombopag

Shionogi Concludes Licensing Agreements with Eddingpharm for Lusutrombopag

June 26, 2019 By americanpharmaceuticalreview

Shionogi announces the Company has concluded an agreement with Eddingpharm to license-out lusutrombopag, a thrombopoietin receptor agonist (brand name in Japan: MULPLETA®).

In China, about 13.6 million adult patients have chronic liver disease and many of them are said to be planning to receive elective invasive therapy. On the other hand, the country faces a chronic shortage of blood for transfusions due to a growing demand for blood during advanced higher-level medical care, in addition to a lower rate of voluntary blood donation as compared to Europe, the U.S., and Japan. Additionally, it is also known that the current stored blood supply in China is at high risk of transfusion-transmitted infections. Under such circumstances, the application of lusutrombopag is a preferable mode of therapy versus platelet transfusion.

Following product approval, it is anticipated that the two parties will further contribute to clinical treatment of patients in China by leveraging Eddingpharm's broad sales network and Shionogi's know-how in developing and marketing lusutrombopag globally. With the execution of this agreement, Eddingpharm will be granted with exclusive license right of lusutrombopag in Mainland China, Hong Kong, and Macau while Shionogi will supply the product to Eddingpharm and receive an upfront payment as well as milestone payments according to post-launch sales periods. It is also agreed that the two companies will cooperate on the application for approval. The Company has been proceeding with preparations toward the application for approval of the product in China.

"We are very excited about this collaboration. This collaboration is an important milestone for patients in China living with chronic liver disease, bringing a well-tolerated and effective treatment option for severe thrombocytopenia that facilitates the management of invasive procedures one step closer to these patients," said Dr. Isao Teshirogi, President and Chief Executive Officer, Shionogi & Co., Ltd.

"The relationship between Eddingpharm and Shionogi started 12 years ago and I am very pleased to establish this long-term collaboration with Shionogi on Mulpleta,” Ni Xin, Chief Executive Officer of Eddingpharm, said. “As a pharmaceutical company with 140 years of history, Shionogi has a proven track record in developing innovative products. It's an honor for Eddingpharm to bring such a high quality medicine Mulpleta to China. Eddingpharm's vision and mission is always to serve patients in China by bringing in global high quality pharmaceutical products. We will work closely with Shionogi to launch Mulpleta in China as soon as possible to help thrombopenia patients in need."

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com

Readers'Comments
Add a comment
Click here to Login or to Register for free. You will be taken back to your selected item after Login/Registration.
More>> MarketNews
More>> Editors’Picks
More>> TopStories
More>> HotTags
Follow Us
CPhI Online Trade Platform: Worldwide|English|中国站
Customer Service:  86-400 610 1188 (9: 00-18: 00, Mon-Fri)
About Us| Contact Us| Terms of Services| Privacy Policy| Intellectual Property Statement| Links | Site Map
Copyright 2006-20 Shanghai Sinoexpo Informa Markets International Exhibition Co. Ltd (All Rights Reserved). ICP 05034851-53
客服
live chat